Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
50.91 USD | -1.60% | -3.54% | -18.86% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation